ConductScience.org, home

Comparison · NCT00980005-sae

Flulaval Group vs Fluzone Group: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Flulaval Group vs Fluzone Group: serious adverse events. Trial comparisons, record NCT00980005-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00980005-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.009480.005160.0174wilson
Risk in group 20.005660.002590.0123wilson
Risk difference, group 1 minus group 20.00382-0.004090.0123newcombe hybrid score
Risk ratio, group 1 over group 21.680.6114.6log
Odds ratio, group 1 over group 21.680.6094.65log
Number needed to harm, for one more participant with a serious adverse event on Flulaval Group than on Fluzone Group262from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Flulaval Group
subjects received Flulaval™ vaccine according to their priming status and age:~* 3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~* 9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid.
101,055EG000
Group 2Fluzone Group
subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~* 3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~* 9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid.
61,061EG001

Harm

What it counts
Total, serious adverse events
Time frame
Solicited AEs: During a 4-day follow-up period (Days 0-3) after vaccination; Unsolicited AEs:During a 28 day follow-up period (Days 0-27) after vaccination.; SAEs: During the entire study period (From Day 0 up to Day 180).

Source ClinicalTrials.gov

Trial

Title
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
NCT number
NCT00980005
Phases
PHASE3
Conditions
Influenza
Interventions
GSK investigational vaccine GSK1557482A, Fluzone®
Lead sponsor
GlaxoSmithKline
Results first posted
2012-02-15

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00980005-sae